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Background: Though antiretroviral therapy (ART) regimens have become progressively less 
toxic, ART-associated toxicity is still pervasive. Dolutegravir (DTG) is an HIV integrase strand 
transfer inhibitor (INSTI), a class of antiretrovirals that are generally well-tolerated by patients. 
However, in the clinic there are reports of unexpectedly high rates of toxicity in cohorts of 
pregnant women such as neural tube defects, and in older patients’ adverse effects such as 
neuropsychiatric disorders. We hypothesized that these adverse effects could be due to DTG-
induced mitochondrial toxicity in the central nervous system. 
Methods: Human neuroblastoma cells were treated with ART regimens that are currently 
considered standard of care for HIV management. The cells were passaged every 4 days with 
standard growth media. Neuroblastoma cells were exposed to 1X or 4X-Cmax of tenofovir, 
emtricitabine, and DTG in single or in combination for 24 hours. We harvested the cells after 24 
hours of treatment to determine the effect of treatment on cell growth, mitochondrial protein 
presence, mitochondrial expression levels, and NMDA receptor protein levels. 
Results: Our preliminary results indicate that DTG has a potentially appreciable effect on both 
mitochondrial function and cholesterol biosynthesis. ATP synthase expression levels appears to 
be relatively unaffected by treatments while expression levels for the other mitochondrial 
complexes appear to be decreased from DTG treatment compared to other single treatments.  
Conclusion: Though DTG in clinical trials has been demonstrated to be a potent treatment for 
HIV viral load, have a high resistance barrier, and low interaction potential, there is still much to 
be understood in terms of toxicity mechanisms. Our study indicates that the clinical safety 
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Brief introduction to HIV/AIDS 
Acquired immunodeficiency syndrome (AIDS) is a condition caused by infection by the 
human immunodeficiency virus (HIV)1. The infection leads to a decrease of CD4+ T cells in 
humans which results in a compromised immune system and increased susceptibility to 
common infections. There are many theories about the origin of HIV, but the most supported 
theory is that the virus originated from monkeys in West Africa2. AIDS was officially described in 
1981 as a new disease when unusual clusters of Pneumocystis pneumonia, Kaposi’s sarcoma, 
and other opportunistic diseases began to spring up in generally healthy men in cities across 
the United States3,4. French scientist Françoise Barré-Sinoussi was the first to isolate the 
causative agent of AIDS in 1983, followed by further research in 1984 by Robert Gallo and Jay 
Levy who made the link between HIV and AIDS5. 
As of 2018, 37.9 million people globally are living with HIV6. The global burden of HIV 
can be measured by both the number of HIV-related deaths (770,000 in 2018) and the number 
of people newly infected with HIV worldwide (1.7 million in 2018). The World Health 
Organization (WHO) has stated that they are aiming for worldwide HIV-related deaths to drop 
to below 400,000 and number of people newly infected with HIV to below 200,000. To reach 
this goal, one of the most important tools to combat the mortality and new infection rates are 
antiretroviral therapy (ART) drugs. ART drugs are life-saving treatment regimens that help 
people who are infected survive significantly longer periods of time. About 62% of people living 
with HIV are on some form of ART7. The functional benefit of ART is two-fold; the treatment 
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helps increase life expectancy by slowing the loss of CD4+ T cells and also suppresses viral load 
in individuals which makes it much less likely to transmit the virus to another person8.  
Though the overall global rate of new cases of HIV infection is slowing, there are some 
areas that are still observing disproportionately high levels of HIV incidence and deaths from 
AIDS due to lack of access to ART drugs. People in the countries of sub-Saharan Africa alone 
account for 17% of all people in the world living with HIV8. Access to frontline ART drugs is 
difficult for countries that do not have the requisite healthcare and economic infrastructure to 
sustain a robust testing, education, and treatment support system. 
HIV life cycle 
The HIV life cycle consists of seven stages: 1) binding, 2) fusion, 3) reverse transcription, 
4) integration, 5) replication, 6) assembly, and 7) budding9. At the beginning of infection, the 
virus binds to the CD4 receptors and CXCR4 co-receptors, utilizing the resulting cross-linkage to 
gain access to the CD4+ T cell via fusion. During fusion, the HIV envelope and CD4 cell 
membrane fuse and allow for the entry of the virus’ functional parts: the HIV RNA, reverse 
transcriptase, integrase, and other necessary viral proteins. Once the virus is inside the cell, it 
utilizes its own reverse transcriptase to form viral DNA via reverse transcription. The resulting 
viral DNA is then integrated into the host DNA by way of the viral integrase. At this point, the 
host cell begins to produce more of the viral RNA and proteins, allowing for the assembly of 
non-infectious HIV at the surface of the cell. Once the new virus is leaves the host cell, HIV 
enzyme protease cleaves long chains of protein to complete the mature infectious virus. The 
HIV life cycle has been an intense area of focus in research as the various classes of ART drugs 
target different parts of the life cycle. 
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Evolution of anti-HIV medications 
  At the beginning of the AIDS epidemic in the U.S., massive drug screening programs 
were conducted to find possible candidates to combat HIV/AIDS. The first candidate to be 
approved was azidothymidine (AZT). Originally developed as a cancer therapy drug, AZT was 
deemed ineffective against cancer. However, in clinical trials for treating people with AIDS, the 
drug decreased deaths and opportunistic infections at the cost of serious adverse effects10. 
Lower doses of the drug proved successful in delaying the onset of AIDS after infection by HIV in 
asymptomatic people, albeit with serious side effects. Based on the mechanism of action, AZT 
falls under a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). After 
the approval of AZT as an anti-HIV medication, additional NRTIs were subsequently discovered 
and approved.  
Though AZT generally worked as intended, HIV accumulated small mutations at a high 
rate due to a high replication rate. The resulting variants developed resistance to AZT 
sometimes in a matter of days11. To combat the resistance developed from single-drug 
treatments, combination therapy of two drugs was first used in 1995. For the most part, people 
who had never previously used ART and were placed on a two-drug regimen had better 
outcomes in terms of the development of resistance when compared to those that only used 
AZT. The advent of dual drug (two NRTI) combination therapy eventually led to the 
development of highly active antiretroviral therapy (HAART). HAART is a treatment regimen 
that uses three or more ART drugs from different classes that target distinct parts of the HIV 
replication cycle12. A new ART drug class called protease inhibitors (PIs) was discovered to 
complement the NRTIs in the triple-drug therapy. The first protease inhibitor to be introduced 
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was saquinavir. In comparison to dual drug combination therapy with the two standard of care 
NRTIs at the time, zalcitabine (ddC) and AZT, the triple-drug combination was more effective in 
health outcomes as well as staving off the development of resistance. 
The next drug class to be discovered was the non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). Based on cost of production and efficacy of treatment, NNRTIs were 
favored over PIs, which has led to an increased prevalence of NNRTI resistance in resource-
limited settings13. Later in the 1990s, it was discovered that in order for HIV to gain access to 
CD4+ T cells, they had to bind to both the main CD4 receptor and a co-receptor, CCR5. Drugs 
such as maraviroc, a CCR5 antagonist, act as a binding inhibitor, preventing HIV from binding to 
the necessary CCR5 co-receptor and thus preventing entry14. The most recent class addition to 
the ART drug repertoire are the integrase strand transfer inhibitors (INSTIs)15. In 2007, first-
generation integrase inhibitors raltegravir and elvitegravir became important components of 
HAART regimens. Though they are effective drugs, there are several pathways for the virus to 
develop resistance. The newest frontline drug is second generation integrase inhibitor 
dolutegravir (DTG). Touted by WHO as the preferred HIV treatment in all populations16, DTG 
has a relatively low production cost, adherence friendly once-daily dosing, and a high barrier to 
the development of resistance.  
Anti-HIV targets 
The different classes of ART drugs target various points of the HIV life cycle to try and 
mitigate the damage the virus will cause. Based on Figure 1, the process of HIV infection to 
replication to dispersal is shown with the different classes of ART labeled according to the 
mechanism of action they undergo17. NRTIs interfere with the reverse transcriptase from the 
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virus, rendering it unable to be transcribed into DNA. By functioning as chain terminators, the 
viral DNA does not have a chance to be formed, which subsequently prevents them integrating. 
There are two known pathways of drug resistance that have been developed against NRTIs. The 
discrimination pathway is when the reverse transcriptase enzyme has a change in primary 
structure that decreases the binding affinity for the foreign NRTI-triphosphate compared to the 
natural nucleoside18. The other pathway is the excision pathway, which is when the reverse 
transcriptase has the ability to remove chain terminators from the 3’ end of the DNA chain after 
it has been incorporated. This prevents early termination and the viral DNA is still able to form. 
As mentioned previously, protease is an important enzyme in the final step in the formation of 
the HIV mature infectious form. PIs prevent the cleavage of HIV Gag and Pol polyproteins, 
preventing the conversion into functional infectious virions19. Mutations that change the 
confirmation of the substrate binding site for proteases can lead to cross-resistance to PIs as 
they will not be able to bind the active site20. The mechanism of action for NNRTIs are different 
from NRTIs though the target remains the reverse transcriptase enzyme. NNRTIs bind to an 
allosteric non-nucleoside binding component, causing a confirmation change in the active site 





Figure 1 Different Mechanisms of Action for Various ART Classes 
INSTIs are the newest group of ART; they target the HIV enzyme integrase, the enzyme 
responsible for integrating the reverse transcribed viral DNA into the host DNA for further 
replication21. The focus of this paper will be on DTG, the latest INSTI to be approved for the 
treatment of all populations. Though there are many documented benefits associated with the 
drug, including a high barrier against development and resistance, there have been reports of 
side effects that include neuropsychiatric symptoms, including depression and/or suicidal 
thoughts or actions22. In a small Dutch cohort of 387 patients on DTG, the researchers observed 
a 14.2% discontinuation rate due to psychiatric side effects23. Other cohorts had found 
discontinuation rates between 10 to 14%23. Out of the three main INSTIs, DTG reports the 
highest number of cases of neuropsychiatric side effects. Combined with the recent cluster of 
cases of neural tube defects in infants exposed to DTG during peri-conception in Botswana, 
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there is evidence to suggest that DTG safety for pregnant women and infants may need to be 
examined further24. 
A possible mechanism that could cause the neuropsychiatric side effects observed in 
DTG patients is NMDA receptor activation that leads to glutamate induced reactive oxygen 
species (ROS) production. Studies have shown that the mitochondria may play an important 
role in the overproduction of ROS with an association with glutamate excitotoxicity25. 
Hypothesis: 
Our hypothesis is that the observed neuropsychiatric and neural tube defects in patients on 
regimens that contained DTG may be due to the effect of DTG-induced mitochondrial toxicity. 
The mitochondrial complexes are governed by mitochondrial genes with the exception of 
Complex II, which is coded by nuclear DNA. What we expect to see is that Complex II remains 
relatively unaffected by DTG treatment because it is reliant upon nuclear DNA as opposed to 
mitochondrial DNA. The central nervous system effect of DTG could be mediating mitochondrial 
and other sources of ROS production such as NMDR glutamate excitotoxicity. 
 





We cultured SH-SY5Y undifferentiated human neuroblastoma cells, a line of neuroblastoma 
cells that were derived from a 4-year-old Caucasian female suffering with neuroblastoma. In 
previous studies, the cells have been used as a target cell in cell-mediated cytoxicity tests26. We 
treated them using three treatment regimens. We used three standard of care drugs for HIV 
treatment: Emtricitabine (FTC), Tenofovir (TDF), and Dolutegravir (DTG). They were also used in 
combinations of TDF/DTG and TDF/FTC/DTG. We used DMSO as our control. Each drug or drug 
combination was administered at the Cmax 1X and 4X concentrations. We counted the cell 
numbers before and after treatment, then examined each of the treatment groups by Western 
Blot and qPCR, looking specifically for the five mitochondrial complexes and NMDA receptor 
levels. 
Results: 
 We counted under a microscope the number of cells that remained alive after treatment. Our 





















































































































































































































Figure 5 Western blot results for mitochondrial complexes protein levels in undifferentiated neuroblastoma cells. The order of 

































































































































































































Figure 6 qPCR results for mitochondrial complexes gene 
expression levels for mitochondrial complex I NDI 
 
Figure 7 qPCR results for mitochondrial complexes gene 
expression levels for mitochondrial complex I ND6 
 
Figure 8 qPCR results for mitochondrial complexes gene 
expression levels for mitochondrial complex II 
 
Figure 9 qPCR results for mitochondrial complexes gene 



































































































Figure 10 qPCR results for mitochondrial complexes gene 
expression levels for mitochondrial complex IV 
 
Figure 11 qPCR results for mitochondrial complexes gene 




The three drug combination at 4X Cmax had the lowest number of remaining cells. In Figure 4, 
the DMSO control is represented by the black line at one. As a relative measure, all treatments 
that involved high concentrations of DTG had much lower NMDA receptor concentration. 
Complex V is relatively unaffected by the drug treatments in Figure 5 while the other complexes 
decrease significantly with a sharp drop in those treatments that included DTG. Figures 6 
through 11 show the results of qPCR for the mitochondrial complexes. The expression levels of 
all complexes appear to be quite similar. Whether DTG has any adverse effects in terms of gene 
expression remains to be seen. 
Discussion: 
Though there is evidence of neuropsychiatric effects resulting from the use of DTG, the 
mechanisms that drives these effects are still in question. Glutamate driven excitotoxicity is an 
important player in signaling within neuronal cells27. Though we saw an appreciable effect of 
DTG treatments on NMDA receptor levels, it is hard to draw conclusions as whether DTG 
directly affects their production. Because we used neuroblastoma cells, signaling pathways are 
not representative of in vivo conditions for neuronal cells. The lack of difference between the 
gene expression levels of the mitochondrial complexes suggest that DTG may not have a direct 
impact on mitochondrial function. Due to the coronavirus pandemic, the potential for this 
project was cut short, with many trial yet to be completed. Both social distancing and stay at 
home orders cut into the time that could have been spent running more trials. With more data 





 ART drugs have evolved considerably over time and treatment regimens have taken 
advantage of combination therapies using drugs from different classes to target various points 
in the HIV life cycle and to avoid building resistance. However, to move forward and try to 
attain the WHO goals of 90% of all people living with HIV knowing their HIV status, 90% of all 
people with diagnosed HIV infection receiving sustained antiretroviral therapy, and 90% of all 
people receiving antiretroviral therapy having viral suppression by 202028 , we will need to gain 
a better understanding of how frontline treatments for HIV affect those from vulnerable 
populations. DTG has shown great promise in terms of its high barrier to developing resistance 
and efficacy in suppressing viral load. However, the unusually high number of discontinuations 
due to neuropsychiatric adverse effects should not be ignored. The link may not be direct, but 
the neural tube defects seen in Botswana29 with an association to mothers exposed to DTG 
peri-conception is more than likely related to the neuropsychiatric effects. Future studies 
should continue to focus mitochondrial dysfunction as a link to neural tube defects30 and how 
integrase inhibitors such as DTG be higher risk for those with a history of neuropsychiatric 
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